Welcome to our dedicated page for Foghorn Therapeutics SEC filings (Ticker: FHTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D burn rates, clinical milestones and intricate chromatin biology risks fill every Foghorn Therapeutics (FHTX) disclosure. Finding the exact trial update or gauging cash runway in a 10-K can feel like decoding epigenetic jargon. If you have ever searched “Foghorn Therapeutics SEC filings explained simply,” you already know the challenge.
Stock Titan turns that complexity into clarity. Our AI reads each document the instant it hits EDGAR, then delivers concise summaries, plain-English definitions and red-flag alerts. Need the latest Foghorn Therapeutics quarterly earnings report 10-Q filing or want to understand the 8-K announcing a new SMARCA2 study cohort? It’s here, parsed and linked to key metrics. Forms covered include:
- 10-K: annual report with AI-highlighted R&D expense trends and Gene Traffic Control platform updates
- 10-Q: quarter-to-quarter pipeline progress and liquidity analysis
- 8-K: material events—trial pauses, collaboration amendments—explained line by line
- Form 4: Foghorn Therapeutics insider trading Form 4 transactions streamed in real time, plus trend charts
- DEF 14A: proxy statement executive compensation breakdown
Professionals use these insights to monitor segment spending, compare enrollment timelines and track Foghorn Therapeutics executive stock transactions Form 4 before catalyst events. Whether you are preparing a valuation model or just want Foghorn Therapeutics annual report 10-K simplified, our platform answers natural language questions such as “What does FHTX report about BRD9 degrader trials?” or “Where can I find FHTX insider Form 4 filings in real time?”—all without sifting through hundreds of pages.
Foghorn Therapeutics Inc. (FHTX) has restructured its real-estate footprint, according to a Form 8-K filed on 1 July 2025.
New Watertown headquarters. On 27 June 2025 the company signed a 108-month lease with ARE-MA Region No. 77, LLC for 72,846 sq ft at 99 Coolidge Avenue, Watertown, MA. The premises will serve as the principal executive offices and support R&D, manufacturing and related activities.
- Lease commencement: 16 July 2025; base rent starts 9.5 months after delivery (targeted 1 Oct 2026).
- Year 1 base rent: $3.9 million (45,000 RSF).
- Year 2 base rent: ≈$5.2 million (60,000 RSF).
- Year 3 base rent: ≈$6.3 million; thereafter 3 % annual escalator beginning 1 Oct 2027.
- Tenant share of operating & tax expenses: ≈22.71 %.
- Two successive 5-year extension options.
Termination of Cambridge lease. Simultaneously, Foghorn executed an agreement with ARE-Tech Square, LLC to end its 81,441 sq ft lease at 500 Technology Square, Cambridge—originally set to run through 30 Sep 2028. The company will pay all rent and other amounts due through the agreed termination date.
Overall, the filing outlines a planned relocation from Cambridge to a purpose-built Watertown facility with staged rent obligations and optional extensions, replacing a larger, costlier lease that would otherwise have run for three additional years.
FAQ
What is the current stock price of Foghorn Therapeutics (FHTX)?
What is the market cap of Foghorn Therapeutics (FHTX)?
What is the core focus of Foghorn Therapeutics Inc.?
How does the Gene Traffic Control platform contribute to their research?
What are the main product candidates in Foghorn's pipeline?
In which therapeutic area does Foghorn primarily operate?
How does Foghorn differentiate its approach from traditional methodologies?
What role do strategic collaborations play in the company’s success?
